1. Home
  2. JAGX vs VIVS Comparison

JAGX vs VIVS Comparison

Compare JAGX & VIVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Jaguar Health Inc.

JAGX

Jaguar Health Inc.

HOLD

Current Price

$0.96

Market Cap

2.2M

Sector

Health Care

ML Signal

HOLD

Logo VivoSim Labs Inc.

VIVS

VivoSim Labs Inc.

HOLD

Current Price

$0.42

Market Cap

2.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
JAGX
VIVS
Founded
2013
2007
Country
United States
United States
Employees
N/A
9
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.2M
2.5M
IPO Year
2014
N/A

Fundamental Metrics

Financial Performance
Metric
JAGX
VIVS
Price
$0.96
$0.42
Analyst Decision
Strong Buy
Analyst Count
1
0
Target Price
$60.00
N/A
AVG Volume (30 Days)
66.1K
4.5M
Earning Date
04-07-2026
06-04-2026
Dividend Yield
N/A
N/A
EPS Growth
82.42
N/A
EPS
N/A
N/A
Revenue
$11,511,000.00
N/A
Revenue This Year
$61.58
$42.38
Revenue Next Year
N/A
$15.42
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.22
$0.43
52 Week High
$8.00
$5.30

Technical Indicators

Market Signals
Indicator
JAGX
VIVS
Relative Strength Index (RSI) 22.36 18.88
Support Level $0.60 N/A
Resistance Level $0.99 $2.21
Average True Range (ATR) 0.24 0.13
MACD -0.13 -0.03
Stochastic Oscillator 0.00 0.72

Price Performance

Historical Comparison
JAGX
VIVS

About JAGX Jaguar Health Inc.

Jaguar Health Inc is a commercial-stage pharmaceutical company developing novel proprietary prescription medicines sustainably derived from plants from rainforest areas for gastrointestinal disease states in humans and animals. The Company focuses on conditions associated with overactive bowel, including chronic debilitating diarrhea, urgency, and bowel incontinence. It operates through two segments: animal health, which develops and commercializes products for animals, and human health, with the human health segment generating the maximum revenue and focusing on products such as Mytesi, focusing on human products, specifically Mytesi, approved for symptomatic relief of non-infectious diarrhea in adults with HIV/AIDS on antiretroviral therapy.

About VIVS VivoSim Labs Inc.

VivoSim Labs Inc formerly, Organovo Holdings Inc is a biotechnology company focused on developing FXR314 in inflammatory bowel disease (IBD), including ulcerative colitis (UC), based on demonstration of clinical promise in three-dimensional (3D) human tissues as well as preclinical data. FXR is a mediator of gastrointestinal and liver diseases. It is now offering liver toxicology predictive screening and research services as well as working on predicting and studying the intestinal side effect profiles of drugs that are therapeutic candidates of pharmaceutical and biotech companies at all stages of drug development.

Share on Social Networks: